Clinical Trials Logo

Refractory Acute Leukemia clinical trials

View clinical trials related to Refractory Acute Leukemia.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03735875 Completed - Clinical trials for Recurrent Acute Myeloid Leukemia

Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia

Start date: January 25, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase Ib/II trial studies the side effects and best dose of venetoclax in combination with quizartinib and how well they work in treating patients with acute myeloid leukemia that has come back or does not respond to treatment, and who are FLT3-mutation positive. Venetoclax and quizartinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00410423 Completed - Clinical trials for Refractory Acute Leukemia

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

Start date: January 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen that is used to treat leukemias that have relapsed or been refractory to treatment.